{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:31:09Z","timestamp":1777419069119,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jjcc.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T07:31:29Z","timestamp":1648452689000},"page":"179-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of lipoprotein (a) on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents"],"prefix":"10.1016","volume":"80","author":[{"given":"Toshio","family":"Kimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokuni","family":"Akahori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagataka","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2022.03.004_bb0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/eurheartj\/ehr479","article-title":"Lower risk of stent thrombosis and restenosis with unrestricted use of \u2018new-generation\u2019 drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"33","author":"Sarno","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0015","first-page":"881","article-title":"Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"90","author":"Sarno","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0020","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4244\/EIJ-D-16-00179","article-title":"Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and resolute integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial","volume":"12","author":"Kang","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0025","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1172\/JCI117598","article-title":"The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp (a) formation in human plasma","volume":"94","author":"Steyrer","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0030","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/01.CIR.91.5.1403","article-title":"Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty","volume":"91","author":"Desmarais","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1253\/circj.69.644","article-title":"Association between plasma lipoprotein(a) concentration and restenosis after stent implantation","volume":"69","author":"Kamitani","year":"2005","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0040","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0735-1097(02)02267-2","article-title":"The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: the Global Evaluation of New Events and Restenosis After Stent Implantation Study","volume":"40","author":"Zairis","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0045","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/clc.21988","article-title":"Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention","volume":"35","author":"Kardys","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0050","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2013.01.014","article-title":"Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies","volume":"227","author":"Qin","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0055","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1253\/circj.CJ-11-0365","article-title":"Usefulness of lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction","volume":"75","author":"Ikenaga","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2014.10.015","article-title":"Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention","volume":"115","author":"Konishi","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0070","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0085","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0090","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0735-1097(99)00486-6","article-title":"Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen","volume":"35","author":"Grewe","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0100","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/01.CIR.94.6.1247","article-title":"Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study","volume":"94","author":"Hoffmann","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0105","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI119753","article-title":"The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor","volume":"100","author":"Argraves","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00041433-199508000-00007","article-title":"Lipoprotein (a) and coronary heart disease","volume":"6","author":"Maher","year":"1995","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0115","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.8503012","article-title":"Proliferation of human smooth muscle cells promoted by lipoprotein(a)","volume":"260","author":"Grainger","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0120","first-page":"240","article-title":"Lipoprotein(a), fibrin binding, and plasminogen activation","volume":"10","author":"Loscalzo","year":"1990","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0125","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0130","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0140","first-page":"S65","article-title":"Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy","volume":"15","author":"Alagona","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0145","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0150","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0155","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.03.004_bb0160","doi-asserted-by":"crossref","first-page":"h4865","DOI":"10.1136\/bmj.h4865","article-title":"Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults","volume":"351","author":"Emdin","year":"2015","journal-title":"BMJ"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:07:02Z","timestamp":1760274422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508722000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0914508722000569"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.03.004","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of lipoprotein (a) on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}